Nectin Announces Extended Series A Financing to Over $25M and Start of Patient Dosing in Phase 1 Clinical Trial of First-in-Class Immunotherapy for Treatment of Patients with Advanced Solid Tumors

Nov 30

Written by Mukul Verma

First-in-Human Phase 1 Clinical Trial in Advanced Solid Tumors is Being Conducted by MD Anderson with an Investment from Cancer Focus Fund ─

NectinCFF

Israeli biotech company begins trial for cancer immuno-oncology solution

Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy